DDInter832 DDInter1588
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tadalafil
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide
Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin